Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab combinations in high grade glioma
NCT04220892Phase 1Withdrawn
- Start
- Jul 2020
- Primary completion
- Jul 2020
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of pembrolizumab in high-grade glioma (HGG) (2 arms). Primary endpoint: Tumor response rates at 1 year. Planned start Jul 2020; status: withdrawn.
02
Drugs
03
Conditions
high-grade glioma (HGG)
Beyond the preview
Go deeper on NCT04220892.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04220892.